EP2476422A4 - Pharmaceutical compositon for anti-thrombotic diseases, its preparation method and use - Google Patents
Pharmaceutical compositon for anti-thrombotic diseases, its preparation method and useInfo
- Publication number
- EP2476422A4 EP2476422A4 EP20090848864 EP09848864A EP2476422A4 EP 2476422 A4 EP2476422 A4 EP 2476422A4 EP 20090848864 EP20090848864 EP 20090848864 EP 09848864 A EP09848864 A EP 09848864A EP 2476422 A4 EP2476422 A4 EP 2476422A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- timosaponin
- pharmaceutical composition
- present
- thrombotic disease
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007536 Thrombosis Diseases 0.000 title abstract 4
- 230000002785 anti-thrombosis Effects 0.000 title 1
- 239000003146 anticoagulant agent Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- MMTWXUQMLQGAPC-YXOKLLKRSA-N Timosaponin A-III Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O MMTWXUQMLQGAPC-YXOKLLKRSA-N 0.000 abstract 3
- XWHLRGYHAKFVSN-NIYSFEGRSA-N Timosaponin AIII Natural products O([C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O[C@H]1O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@@H](C)CC1)O5)C)[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O XWHLRGYHAKFVSN-NIYSFEGRSA-N 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- MMTWXUQMLQGAPC-XWIAVXRASA-N timosaponin A-III Natural products C[C@@H]1CC[C@@]2(OC1)O[C@@H]3C[C@H]4[C@H]5CC[C@@H]6C[C@H](CC[C@]6(C)[C@H]5CC[C@]4(C)[C@@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@H](O)[C@H](O)[C@H]7O[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O MMTWXUQMLQGAPC-XWIAVXRASA-N 0.000 abstract 3
- SORUXVRKWOHYEO-UHFFFAOYSA-N timosaponin B-II Natural products O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)CCC3C4(C)CC5)C)(O)OC1CC2C3CCC4CC5OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O SORUXVRKWOHYEO-UHFFFAOYSA-N 0.000 abstract 3
- UDUSTUNNFSNCPR-QFNYSWOCSA-N timosaponin BII Natural products C[C@H](CC[C@@]1(O)O[C@H]2C[C@H]3[C@@H]4CC[C@@H]5C[C@H](CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2[C@@H]1C)O[C@@H]6O[C@H](CO)[C@H](O)[C@H](O)[C@H]6O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O UDUSTUNNFSNCPR-QFNYSWOCSA-N 0.000 abstract 3
- SORUXVRKWOHYEO-UJDJZYEZSA-N timosaponin bii Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SORUXVRKWOHYEO-UJDJZYEZSA-N 0.000 abstract 3
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 208000034158 bleeding Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2009/001009 WO2011026259A1 (en) | 2009-09-07 | 2009-09-07 | Pharmaceutical compositon for anti-thrombotic diseases, its preparation method and use |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2476422A1 EP2476422A1 (en) | 2012-07-18 |
EP2476422A4 true EP2476422A4 (en) | 2013-04-24 |
EP2476422B1 EP2476422B1 (en) | 2016-03-16 |
Family
ID=43648827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09848864.6A Active EP2476422B1 (en) | 2009-09-07 | 2009-09-07 | Pharmaceutical compositon comprising timosaponin a-iii and timosaponin b-ii |
Country Status (6)
Country | Link |
---|---|
US (1) | US20120316122A1 (en) |
EP (1) | EP2476422B1 (en) |
JP (1) | JP5606532B2 (en) |
KR (1) | KR101667224B1 (en) |
HK (1) | HK1167085A1 (en) |
WO (1) | WO2011026259A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103540640B (en) * | 2012-07-09 | 2015-05-20 | 上海中医药大学 | Preparation method of timosaponin A III |
KR101376188B1 (en) * | 2012-12-13 | 2014-03-20 | 한국 한의학 연구원 | External composition and cosmetic composition for skin moisturizing or improving skin wrinkle |
CN104606460A (en) * | 2015-02-05 | 2015-05-13 | 李念虎 | Prescription for treating diabetes mellitus caused by yin deficiency and dryness heat and preparation method of prescription |
CN104840593A (en) * | 2015-05-04 | 2015-08-19 | 郭淑权 | Chinese medicine preparation for curing cerebral vascular stress ulcer bleeding |
CN110623965B (en) * | 2019-10-24 | 2022-09-16 | 上海市第五人民医院 | Timosaponin composition and application thereof in treating viral myocarditis |
CN110882266B (en) * | 2019-10-24 | 2022-09-16 | 上海市第五人民医院 | Timosaponin composition and application thereof in treating viral myocarditis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1451384A (en) * | 2003-05-09 | 2003-10-29 | 中国人民解放军第二军医大学 | Use of timosaponin for preparing medicine for preventing and treating brain apoplexy |
EP1741434A1 (en) * | 2004-04-29 | 2007-01-10 | Institute of Radiation Medicine, Academy of Military Medical Sciences Pla | The use of timosaponin bii in preparing the drug or produce of preventing and treating stroke |
WO2009151762A2 (en) * | 2008-04-11 | 2009-12-17 | Bionovo, Inc. | Anticancer methods using extracts of anemarrhena asphodeloides bunge |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628790A (en) | 2004-08-31 | 2005-06-22 | 中国人民解放军第二军医大学 | Injecta of anemarrhena extractive |
JP2012500776A (en) * | 2008-04-11 | 2012-01-12 | バイオノボ・インコーポレーテッド | ANTI-CANCER METHOD USING AN EXTRACT OF HANASGE ANEMARRHENAASPHODELOIDESBUNGE |
CN101658525B (en) * | 2008-08-28 | 2012-05-30 | 北京四环制药有限公司 | Medicinal composition for resisting thrombotic diseases, preparation method thereof and application thereof |
-
2009
- 2009-09-07 WO PCT/CN2009/001009 patent/WO2011026259A1/en active Application Filing
- 2009-09-07 KR KR1020127008858A patent/KR101667224B1/en active IP Right Grant
- 2009-09-07 US US13/394,375 patent/US20120316122A1/en not_active Abandoned
- 2009-09-07 JP JP2012527172A patent/JP5606532B2/en active Active
- 2009-09-07 EP EP09848864.6A patent/EP2476422B1/en active Active
-
2012
- 2012-08-07 HK HK12107753.8A patent/HK1167085A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1451384A (en) * | 2003-05-09 | 2003-10-29 | 中国人民解放军第二军医大学 | Use of timosaponin for preparing medicine for preventing and treating brain apoplexy |
EP1741434A1 (en) * | 2004-04-29 | 2007-01-10 | Institute of Radiation Medicine, Academy of Military Medical Sciences Pla | The use of timosaponin bii in preparing the drug or produce of preventing and treating stroke |
WO2009151762A2 (en) * | 2008-04-11 | 2009-12-17 | Bionovo, Inc. | Anticancer methods using extracts of anemarrhena asphodeloides bunge |
Non-Patent Citations (1)
Title |
---|
See also references of WO2011026259A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011026259A1 (en) | 2011-03-10 |
EP2476422B1 (en) | 2016-03-16 |
JP2013503821A (en) | 2013-02-04 |
US20120316122A1 (en) | 2012-12-13 |
EP2476422A1 (en) | 2012-07-18 |
KR101667224B1 (en) | 2016-10-18 |
JP5606532B2 (en) | 2014-10-15 |
HK1167085A1 (en) | 2012-11-23 |
KR20120056290A (en) | 2012-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA86614C2 (en) | Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine | |
EP2476422A4 (en) | Pharmaceutical compositon for anti-thrombotic diseases, its preparation method and use | |
WO2008079291A3 (en) | Substituted heterocycles and methods of use | |
MX2011012183A (en) | Parmaceutical composition for the treatment of heart diseases. | |
WO2009033733A3 (en) | Use of apeptide as a therapeutic agent | |
WO2009033799A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009046824A3 (en) | Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis | |
WO2009033740A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033758A3 (en) | Use of the peptide phpfhffvyk as therapeutic agent | |
WO2009033667A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009039973A3 (en) | Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent | |
WO2009040021A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009033737A3 (en) | Use of gluten exorphin c : as a therapeutic agent | |
WO2009033714A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009040073A3 (en) | Use of a peptide as a therapeutic agent | |
WO2009039986A3 (en) | Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent | |
MX2020012377A (en) | Use of riluzole oral disintigrating tablets for treating diseases. | |
WO2009043440A3 (en) | Use of il-1 receptor peptide, alone or in combination with d-ala-gln-octadecyl ester, as a therapeutic agent | |
PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
WO2009033786A3 (en) | Use of a peptide as a therapeutic agent | |
MX336278B (en) | Compositions and methods for prevention and treatment of wounds. | |
NZ596218A (en) | Bssl antagonists for treatment of inflammatory diseases | |
MX350662B (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl) -5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions. | |
EA201171229A1 (en) | THERAPEUTIC APPLICATION OF HINAZOLINDION DERIVATIVES IN CARDIOVASCULAR DISEASES | |
WO2009040067A3 (en) | Use of a peptide as a therapeutic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120330 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1167085 Country of ref document: HK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130326 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/58 20060101ALI20130320BHEP Ipc: A61K 36/8964 20060101ALI20130320BHEP Ipc: A61P 9/10 20060101ALI20130320BHEP Ipc: A61P 7/02 20060101ALI20130320BHEP Ipc: A61K 31/7048 20060101ALI20130320BHEP Ipc: A61P 3/10 20060101ALI20130320BHEP Ipc: A61K 31/704 20060101AFI20130320BHEP |
|
17Q | First examination report despatched |
Effective date: 20150323 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITA |
|
INTG | Intention to grant announced |
Effective date: 20151012 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 780599 Country of ref document: AT Kind code of ref document: T Effective date: 20160415 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009036899 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160617 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160616 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 780599 Country of ref document: AT Kind code of ref document: T Effective date: 20160316 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160716 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160718 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009036899 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
26N | No opposition filed |
Effective date: 20161219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160616 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1167085 Country of ref document: HK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160907 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160930 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160907 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20090907 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160930 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230810 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230925 Year of fee payment: 15 Ref country code: DE Payment date: 20230816 Year of fee payment: 15 |